Profile on Cel-Sci Corporation (CVM)
Profile : Cel-Sci Corporation (CVM)
 |
|
Latest Newsletter Editions on CVMMon, Jun 15, 2009 @ 03:19 pm
Last week I took a pretty detailed look at how the market - the S&P 500 in this case - wasn't exactly as bearish as everyone thought it might be, but was instead simply trapped in a range... between 926 and 950. Though I was generally bearish, I had no real 'supporting evidence' for my thesis. I...
Sat, Jan 10, 2009 @ 01:07 pm
When we published our recommendation of CEL-SCI (AMEX: CVM) shares on Wednesday morning of this week, we really had no idea some of you would be able to exit at our target price of 40 cents by Thursday afternoon. I've triple-checked it since then though, and it's true - there were a few transactions...
Wed, Jan 7, 2009 @ 05:24 am
With both the market and the economy apparently poised to begin improving, I know we're all interested in trading ideas that will start the portfolio-recovery process. What's interesting about today's idea, though, is how the bear market may have actually obscured the opportunity's development. Today...
Sat, Mar 8, 2008 @ 01:04 pm
No small cap suggestion for today, which is fine actually ...there are more important things to talk about after Friday's bearish end to an even more bearish week. The last time we looked, all the indices were toying with another breakdown. We pretty much got to the proverbial fork in the road after...
Thu, Dec 20, 2007 @ 01:54 pm
The end of the year is right around the corner, and I for one am glad. We've been itching to close the books on a handful of our followings, and perhaps benefit from a tax loss (since they didn't benefit us in many other ways). At the same time, there are also a few names we want to be sure to keep...
Click Here For More Newsletters on CVM |
Latest Blog Entries on CVMTue, Sep 22, 2009 @ 09:11 am
It’s hard to believe that CEL-SCI (CVM), which was only trading at $0.27 when we suggested it in January, has rallied more than 600%, and is currently priced around $1.85. THAT is the reason we focus on small and micro cap stocks… big winners are uncommon, but when you do latch onto one, wow!
That being [...]
Tue, Jun 9, 2009 @ 06:49 am
How do you make a biotech stock gain 77% in one day? Have the company unveil a potential treatment for swine flu that (1) works, and (2) doesn’t cause a host of side effects in a swine flu patient that could actually make their illness worse rather than better. Take CEL-SCI Corp. (CVM) as an [...]
Mon, Jan 12, 2009 @ 02:08 pm
Normally we don’t take activist stances, opting to play the hand we’re dealt rather than trying to predetermine the hand we get. Given the situation though (not just for a particular company, but for our tax money as well), maybe it’s not out of place for us to shake the chains a little, and let [...]
Wed, Aug 20, 2008 @ 05:37 am
It had been a while since we heard anything from biotech company CEL-SCI (CVM), but that changed yesterday with a fat dose of encouraging news. Teva Pharmaceuticals (TEVA) has been signed as an exclusive licensee of CEL-SCI’s cancer treatment - Multikine - for Turkey and Israel. What’s interesting here is that Teva got on board even [...]
Thu, Jun 19, 2008 @ 08:10 am
I really thought this week’s news would get biotech stock CEL-SCI (CVM) moving again. And it did…..for a while. We saw little follow-through on the chart though. Even so, CEL-SCI is still one of our favorite longer-term ideas.
If you didn’t hear, CEL-SCI announced they’ve discovered an effective treatment for rheumatoid arthritis. They’re calling it CEL-2000 for [...]
|
Quote Data : CEL-SCI Corp. (CVM)
|
|
Insider Transactions - Balance Sheet |
+0.0100 (+0.78%)
Business Summary : Cel-Sci Corporation (CVM)
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.
Disclosure
Disclaimer:
TGR Group LLC has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company. Additionally, back in February of 2006, TGR Group LLC was paid a fee of $25,000 and 150,000 shares of newly issued restricted stock by Cel-Sci for coverage of the Company. The aforementioned 150,000 restricted shares became free trading under SEC rule 144 and were sold in the open market prior to the company entering into a new contract agreement with TGR Group in January of 2009. Additionally, back in November of 2002, TGR Group LLC was paid a fee of $25,000 and 250,000 shares of newly issued restricted stock of Cel-Sci for coverage of the company. The aforementioned 250,000 restricted shares became free trading under SEC rule 144 and were sold in the open market prior to the company entering into a new contract agreement with TGR Group in February of 2006.
Current Position as of 11/13/09:
30,000 Shares
Total Dollars Liquidated as of 11/13/09:
$32,309.01
TGR Group LLC has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company. Additionally, back in February of 2006, TGR Group LLC was paid a fee of $25,000 and 150,000 shares of newly issued restricted stock by Cel-Sci for coverage of the Company. The aforementioned 150,000 restricted shares became free trading under SEC rule 144 and were sold in the open market prior to the company entering into a new contract agreement with TGR Group in January of 2009. Additionally, back in November of 2002, TGR Group LLC was paid a fee of $25,000 and 250,000 shares of newly issued restricted stock of Cel-Sci for coverage of the company. The aforementioned 250,000 restricted shares became free trading under SEC rule 144 and were sold in the open market prior to the company entering into a new contract agreement with TGR Group in February of 2006.
Current Position as of 11/13/09:
30,000 Shares
Total Dollars Liquidated as of 11/13/09:
$32,309.01
Recent News Headlines
Fri, 20 Nov 2009 11:01:45 Etc/GMT
Wed, 18 Nov 2009 14:45:00 Etc/GMT
CEL-SCI Corporation , a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine .
Mon, 16 Nov 2009 09:29:10 Etc/GMT
Mon, 16 Nov 2009 07:58:41 Etc/GMT
Thu, 12 Nov 2009 12:30:00 Etc/GMT
LOS ANGELES----BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that after the market closed on Tuesday, investors of CEL-SCI Corporation learned that the company had filed an "amended" Form S-3 with the SEC.
Thu, 12 Nov 2009 10:21:52 Etc/GMT
Tue, 10 Nov 2009 15:54:44 Etc/GMT
Mon, 9 Nov 2009 14:40:00 Etc/GMT
CEL-SCI Corporation announced today that Dr. Kenneth S. Rosenthal, Professor of Immunology and Microbiology of Northeastern Ohio Universities College of Medicine and Pharmacy, reported on work conducted in collaboration with scientists at the Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology.
Mon, 9 Nov 2009 14:00:09 Etc/GMT
Mon, 9 Nov 2009 13:26:00 Etc/GMT
LOS ANGELES----BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that On Monday and Tuesday of this week, the 7th Annual Vaccines: All Things Considered Conference is taking place in Washington, DC.
Mon, 9 Nov 2009 08:25:14 Etc/GMT
Sun, 8 Nov 2009 16:54:50 Etc/GMT
Fri, 6 Nov 2009 19:38:00 Etc/GMT
Drug stocks gain while shares of Alkermes Inc. fall after the company issues its fiscal second-quarter earnings report and lowers its financial forecast.
Fri, 6 Nov 2009 17:34:00 Etc/GMT
LOS ANGELES----BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that one of several expected key news developments has been announced by CEL-SCI Corporation , today.
Fri, 6 Nov 2009 15:53:41 Etc/GMT
Fri, 6 Nov 2009 15:38:00 Etc/GMT
Drug stocks are mixed in early trading as shares of Alkermes Inc. fall after it issues its fiscal second-quarter earnings report and lowers its financial forecast.
Fri, 6 Nov 2009 15:15:00 Etc/GMT
67 WALL STREET, New York - November 6, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Fri, 6 Nov 2009 14:45:00 Etc/GMT
CEL-SCI Corporation , a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that an Institutional Review Board of The Johns Hopkins University School of Medicine has given clearance for the Company's first clinical study to proceed.
Fri, 6 Nov 2009 12:00:00 Etc/GMT
Thu, 5 Nov 2009 19:32:08 Etc/GMT
